Geneseeq received China’s NMPA approval for its NTRK fusion detection kit, PanTRKare, as a companion diagnostic for Vcare PharmaTech’s TRK inhibitor Velmarto. The sequencing-based assay is intended to identify NTRK fusion-positive solid tumors and support appropriate patient selection. The NMPA clearance matters for TRK-targeted oncology because companion diagnostics directly shape eligible populations and can determine the real-world prescribing funnel once a therapy enters clinical practice. Geneseeq’s approval also signals continued regulatory support for lab-developed molecular assays transitioning into formal CDx status, where performance requirements tighten and reimbursement pathways often follow. For Velmarto, the move provides a regulatory-backed route to identify patients likely to benefit from the treatment’s intended mechanism of action.